Langerhans cell histiocytosis

Archives of Disease in Childhood

Volumn 94, Issue 11, 2009, Pages 904-908

  Windebank, K ^a   Nanduri, V ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b WATFORD GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CYCLOSPORIN; ETOPOSIDE; INDOMETACIN; LANGERIN; METHOTREXATE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PREDNISOLONE; STEROID; T6 ANTIGEN; TACROLIMUS; VINBLASTINE;

BONE LESION; BONE MARROW; BONE RADIOGRAPHY; CLINICAL FEATURE; CONDUCTION DEAFNESS; CURETTAGE; CYTOPENIA; DRUG MEGADOSE; ECZEMA; EOSINOPHILIC GRANULOMA; GASTROINTESTINAL TRACT; GROWTH HORMONE DEFICIENCY; HEPATOSPLENOMEGALY; HISTIOCYTOSIS X; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LIVER FUNCTION TEST; LUNG DISEASE; LUNG FUNCTION TEST; MORBIDITY; NEUROLOGICAL COMPLICATION; PRIORITY JOURNAL; REVIEW; SCLEROSING CHOLANGITIS; SKIN BIOPSY; SKIN DISEASE; VESTIBULAR DISORDER;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; INFANT, NEWBORN; MAGNETIC RESONANCE IMAGING; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70350449239     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.125872     Document Type: Review

References (50)

1. Langerhans P. Uber die nerven der menschlichen haut. Arch Pathol Anat 1868;44:325-7.
2. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer 1999;35:747-67; discussion 67-9.
3. Lichtenstein L. Histiocytosis X: integration of eosiniphilic granuloma of the bone, Letterer-Siwe disease and Schuller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol 1953;56:84-102.
4. Nezelof C, Basset F. From histiocytosis X to Langerhans cell histiocytosis: a personal account. Int J Surg Pathol 2001;9:137-46.
5. Risdall RJ, Dehner LP, Duray P, et al. Histiocytosis X (Langerhans' cell histiocytosis). Prognostic role of histopathology. Arch Pathol Lab Med 1983;107:59-63.
6. Chu T, D'Angio GJ, Favara B, et al. Histiocytosis syndromes in children. Lancet 1987;1:208-9.
7. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other Langerin-expressing dendritic cells. Nat Rev Immunol 2008;8:935-47.
8. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.[see comment] [erratum appears in J Pediatr 2001;139:170]. J Pediatr 2001;138:728-34.
9. Nezelof C, Basset F. An hypothesis Langerhans cell histiocytosis: the failure of the immune system to switch from an innate to an adaptive mode. Pediatr Blood Cancer 2004;42:398-400.
10. Bechan GI, Meeker AK, De Marzo AM, et al. Telomere length shortening in Langerhans cell histiocytosis. Br J Haematol 2008;140:420-8.
11. Egeler RM, Favara BE, van Meurs M, et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 1999;94:4195-201.
12. Haupt R, Nanduri V, Egeler R. Late effects of Langerhans cell histiocytosis and its association with malignancy. In: Weitzman S, Egeler M, eds. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press, 2005:272-92.
13. Feldman AL, Berthold F, Arceci RJ, et al. Clonal relationship between precursor Tlymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol 2005;6:435-7.
14. Haupt R, Fears TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations. Int J Cancer 1997;71:9-13.
15. Guyot-Goubin A, Donadieu J, Barkaoui M, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004.[see comment]. Pediatr Blood Cancer 2008;51:71-5.
16. Salotti J, Nanduri V, Pearce M, et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child 2009;94:376-80.
17. Arico M, Danesino C. Langerhans' cell histiocytosis: Is there a role for genetics? Haematologica 2001;86:1009-14.
18. Bernstrand C, Cederlund K, Sandstedt B, et al. Pulmonary abnormalities at longterm follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol 2001;36:459-68.
19. de Berker D, Lever LR, Windebank K. Nail features in Langerhans cell histiocytosis. Br J Dermatol 1994;130:523-7.
20. Stalemark H, Laurencikas E, Karis J, et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 2008;51:76-81.
21. Hashimoto K, Bale GF, Hawkins HK, et al. Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker type). Int J Dermatol 1986;25:516-23.
22. Arico M. LCH-Adult-1. Histiocyte Society 2007. http://www.histio.org/ site/c. kiKTL4PQLvF/b.1767369/k.AAF9/Current-Treatment-Protocols.htm (accessed 25 May 2009).
23. Tatevossian R, Nanduri V, Salotti J, et al. Adults with LCH-orphans with an orphan disease. Clin Med 2006;6:404-8.
24. Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006;27:1272-85.
25. Donadieu J, Piguet C, Bernard F, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:770-6.
26. Howarth DM, Mullan BP, Wiseman GA, et al. Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disorders. J Nucl Med 1996;37:1456-60.
27. Kaste SC, Rodriguez-Galindo C, McCarville ME, et al. PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol 2007;37:615-22.
28. Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36:1019-31.
29. Hait E, Liang M, Degar B, et al. Gastrointestinal tract involvement in Langerhans cell histiocytosis: case report and literature review. Pediatrics 2006;118:e1593-9.
30. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2- chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005;41:2682-9.
31. Minkov M, Potschger U, Grois N, et al. Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer 2007 Oct 15;49:694-8.
32. Broadbent V, Gadner H, Komp DM, et al. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol 1989;17:492-5.
33. Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans' cell histiocytosis. Thorax 2000;55:405-16.
34. Braier J, Latella A, Balancini B, et al. Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:765-9.
35. Odame I, Li P, Lau L, et al. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. Pediatr Blood Cancer 2006;47:889-93.
36. Yule SM, Hamilton JR, Windebank KP. Recurrent pneumomediastinum and pneumothorax in Langerhans cell histiocytosis. Med Pediatr Oncol 1997;29:139-42.
37. Jaffe R. Liver involvement in the histiocytic disorders of childhood. Pediatr Dev Pathol 2004;7:214-25.
38. Hoeger PH, Nanduri VR, Harper JI, et al. Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis. Arch Dis Child 2000;82:483-7.
39. Munn SE, Olliver L, Broadbent V, et al. Use of indomethacin in Langerhans cell histiocytosis.[see comment]. Med Pediatr Oncol 1999;32:247-9.
40. Grois N, Gadner H. Re: Is unifocal Langerhans cell histiocytosis of the orbit a ''CNSrisk'' lesion? Pediatr Blood Cancer 2004;43:301-2.
41. Arzoo K, Sadeghi S, Pullarkat V. Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.[see comment]. N Engl J Med 2001;345:225.
42. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol 1993;21:259-64.
43. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994;23:72-80.
44. Weitzman S, Egeler RM. Histiocytic disorders of children and adults. Cambridge: Cambridge University Press, 2005.
45. Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008;111:2556-62.
46. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatmentresistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215-25.
47. Nanduri VR, Pritchard J, Levitt G, et al. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer 2006;42:2563-9.
48. Nanduri VR, Pritchard J, Chong WK, et al. Labyrinthine involvement in Langerhans' cell histiocytosis. Int J Pediatr Otorhinolaryngol 1998;46:109-15.
49. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-44.
50. Braier J, Ciocca M, Latella A, et al. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol 2002;38:178-182